RecruitingPhase 1NCT07413133

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

A Phase 1 Pharmacokinetic Study in Healthy Adult Volunteers to Evaluate the Bioavailability of ABBV-8736 Following Subcutaneous Administration Relative to Intravenous Administration

Sponsor

AbbVie

Enrollment

40 participants

Start Date

Feb 11, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteer

Summary

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria3

Body mass index (BMI) is >= 18.0 to <= 32.0 kg/m2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
Body weight >= 35 kg.
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).

Exclusion Criteria4

Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements, on a regular basis.
Participant uses any medications, vitamins and/or herbal supplements within the 14-day period prior to study treatment administration.
Participant has received any treatment by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study treatment administration.
Participant has prior exposure to a Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) agent.

Interested in this trial?

Get notified about updates and connect with the research team.